Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

The Plant-Based / Psychedelics Hybrid Co. “Positioned For Growth”

(Click image to play video) M eet the Company and its CEO that’s positioning itself to be the premier cannabis commercialization extractor and manufacturing partner for functional psychedelic mushroom companies. Based on extensive extractio...
Dave Jackson | November 2, 2020 |

Valeo Pharma Big Pharma Capabilities Presents Opportunity

Valeo Pharma Inc. is a Canadian specialty pharmaceutical company with big pharma capabilities while retaining small company flexibilities. Valeo is a fast-growing revenue generating company with a strong product portfolio and a robust product pipeline. Valeo Pharma In...
Fredrick William | May 15, 2020 |

Arcadia Ropes in $3 Million in GoodHemp Seed Purchase Orders Within 50 Days of Product Launch

Arcadia Biosciences shares traded 25% higher after reporting that it secured $3 million in pre-season GoodHemp seed purchase commitments in just 50 days after launching the product. Arcadia Biosciences Inc. (RKDA:NASDAQ) , which employs science-based approac...
Streetwise Reports | January 31, 2020 |

Siyata Mobile Accelerating Growth on Multiple Fronts

Expands its Global Footprint with Multiple New Contracts and a Key E-Commerce Distribution Agreement and Launches Innovative New Product Focusing on one specific niche market has long been a proven path to success. It’s also a potential road to failure if y...
Featured Submission | September 29, 2021 |

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%

Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. Biopharmaceutical maker Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) yesterday announced financial and ...
Streetwise Reports | August 6, 2019 |

Siyata Mobile Still Bullish After Q2 Earnings Call

Earnings reports are useful for measuring financial milestones, but they don’t tell the whole story. Siyata Mobile (NASDAQ: SYTA, SYTAW) released their Q2 earnings on an October 15th call that included CEO Marc Seelenfreund, VP of Corporate Development Daniel...
Featured Submission | October 27, 2021 |

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales

Shares in Puma Biotechnology are trading 20% higher today after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. Biopharmaceutical company Puma Biotechnology Inc. (PBYI:NADSAQ) shares opened more than 20% higher to...
Streetwise Reports | August 14, 2019 |

Lannett Signs Exclusive U.S. Distribution Deal with Sinotherapeutics; Shares Up 40%

Shares of Lannett Co. are up 40% today after announcing that it secured rights to be the exclusive U.S. distributor of Sinotherapeutics' antifungal drug that is an AB-rated generic for Noxafil. This morning generic drug maker Lannett Company Inc. (LCI:NYSE.MKT) anno...
Streetwise Reports | August 29, 2019 |

Ocular Therapeutix Shares Climb More than 25% on Q4 Revenue and Phase 1 Wet AMD Clinical Data

Ocular Therapeutix shares set a new 52-week high price after the company reported preliminary FY/19 revenue results along with positive interim data from its Phase 1 clinical study of OTX-TKI for treatment of wet age-related macular degeneration. Ocular Ther...
Streetwise Reports | March 5, 2020 |

Biotech to Test Stem Cell Product in COVID-19-Caused Acute Respiratory Distress

A description of Mesoblast's multi-site clinical trial and possible implication for the therapeutic are provided in an H.C. Wainwright & Co. report. In an April 9 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Mesoblast Lt...
Streetwise Reports | April 16, 2020 |
1 2 3 4 5 6 7 8 9 10 ...